Santa Rosa, Calif.-based Boericke & Tafel is supporting mass market launch of Novitra cold sore remedy with consumer print, radio ad campaign slated to begin in first quarter 2003. Designed by Stratagem Health Communications (San Francisco), ad push will feature "zoned" approach, starting in the mountain states and Northwest. Novitra 1Web site features educational, promotional materials and coupons. Homeopathic zincum oxydatum cream in .25 oz. tubes retails for approximately $12.99, carries "immediate action" and "clinically proven to shorten the duration of cold sores" claims. Now reaching shelves at Wal-Mart, Target, Novitra also is sold at major food, drug outlets nationwide...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
